188 related articles for article (PubMed ID: 37901764)
1. Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials.
Tan DJH; Tang ASP; Lim WH; Ng CH; Nah B; Fu C; Xiao J; Koh B; Tay PWL; Tan EX; Teng M; Syn N; Muthiah MD; Tamaki N; Lee SW; Kim BK; Yau T; Vogel A; Loomba R; Huang DQ
Liver Cancer; 2023 Oct; 12(5):445-456. PubMed ID: 37901764
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
4. Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials.
Brown TJ; Gupta A; Sedhom R; Beg MS; Karasic TB; Yarchoan M
Gastrointest Tumors; 2022 Mar; 9(1):19-26. PubMed ID: 35528745
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials.
Cabibbo G; Cucchetti A; Cammà C; Casadei-Gardini A; Celsa C; Emanuele Maria Rizzo G; Johnson P; Ercolani G
Future Oncol; 2019 Oct; 15(29):3411-3422. PubMed ID: 31588789
[No Abstract] [Full Text] [Related]
6. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman O; Elsayed Z
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis.
Oranratnachai S; Rattanasiri S; Pooprasert A; Tansawet A; Reungwetwattana T; Attia J; Thakkinstian A
Front Oncol; 2021; 11():654020. PubMed ID: 33869060
[TBL] [Abstract][Full Text] [Related]
8. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
[TBL] [Abstract][Full Text] [Related]
9. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
[TBL] [Abstract][Full Text] [Related]
10. First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis.
Fong KY; Zhao JJ; Sultana R; Lee JJX; Lee SY; Chan SL; Yau T; Tai DWM; Sundar R; Too CW
Liver Cancer; 2023 Feb; 12(1):7-18. PubMed ID: 36872922
[TBL] [Abstract][Full Text] [Related]
11. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
Peng S; Zhao Y; Xu F; Jia C; Xu Y; Dai C
PLoS One; 2014; 9(12):e112530. PubMed ID: 25460347
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis.
Yang S; Zhou Y; Zeng L
Adv Clin Exp Med; 2023 Aug; 32(8):839-845. PubMed ID: 37140014
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma.
Wang C; Lu Y; Wang H; Gao X; Bai W; Qu J; Xu G; Zhang Z; Zeng Z; Zhou L; An L; Lv J; Yang Y
Exp Ther Med; 2012 Aug; 4(2):188-196. PubMed ID: 23139708
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
15. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.
Abou-Alfa GK; Shi Q; Knox JJ; Kaubisch A; Niedzwiecki D; Posey J; Tan BR; Kavan P; Goel R; Lammers PE; Bekaii-Saab TS; Tam VC; Rajdev L; Kelley RK; El Dika I; Zemla T; Potaracke RI; Balletti J; El-Khoueiry AB; Harding JJ; Suga JM; Schwartz LH; Goldberg RM; Bertagnolli MM; Meyerhardt J; O'Reilly EM; Venook AP
JAMA Oncol; 2019 Nov; 5(11):1582-1588. PubMed ID: 31486832
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma.
Delos Santos S; Udayakumar S; Nguyen A; Ko YJ; Berry S; Doherty M; Chan KKW
Curr Oncol; 2020 Dec; 27(6):300-306. PubMed ID: 33380861
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
[TBL] [Abstract][Full Text] [Related]
19. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study.
Qiu Z; Shen L; Jiang Y; Qiu J; Xu Z; Shi M; Yu Z; Ma Y; He W; Zheng Y; Li B; Wang G; Yuan Y
Ann Transl Med; 2021 Feb; 9(4):283. PubMed ID: 33708910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
